Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study

Sanjiv Patel, Relay Therapeutics CEO May 19, 2026 07:13 AM EDT R&D Re­lay's PI3Kα in­hibitor clears ef­fi­ca­cy bar in Phase 2 vas­cu­lar anom­alies study Ayisha Sharma News Reporter Re­lay Ther­a­peu­tics’ first da­ta read­out for zove­g­al­is­ib in a rare ge­net­ic dis­ease beat Wall Street ex­pec­ta­tions, ex­pand­ing the PIK3α in­hibitor’s R&D prospects be­yond breast can­cer. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER